Document Detail

Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
MedLine Citation:
PMID:  20346239     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: Visfatin is an insulin-mimetic adipokine. In non-rheumatoid arthritis (RA) patients circulating levels of visfatin are correlated with the amount of visceral fat. Recent studies have disclosed an implication of visfatin in inflammation. Chronic systemic inflammation is of major importance in the development of atherosclerosis in RA. In the present study we investigated whether inflammation, obesity or metabolic syndrome are potential determinants of circulating visfatin concentrations in a group of RA patients on periodical treatment with the TNF-alpha blocker infliximab due to severe disease. We also assessed whether the infusion of infliximab may alter circulating visfatin concentrations in patients with severe RA. METHODS: We investigated 33 non-diabetic patients with RA on periodical treatment with infliximab. Serum visfatin levels were determined immediately prior to and after infliximab infusion. RESULTS: There was no correlation between body mass index of RA patients and baseline serum level of visfatin. Also, no significant correlations between baseline visfatin levels and the age at the time of the study or at the onset of the disease, disease duration, ESR and CRP levels, DAS28, lipids, insulin sensitivity, resistin or the cumulative prednisone dose at the time of the study were found. Visfatin levels did not change upon infliximab infusion. CONCLUSIONS: In RA patients on TNF-alpha blocker treatment, circulating visfatin levels are unrelated to disease activity, adiposity or metabolic syndrome. The beneficial effect of anti-TNF-alpha therapy on cardiovascular mortality in RA does not seem to be mediated by changes in serum levels of visfatin.
M A Gonzalez-Gay; T R Vazquez-Rodriguez; M T Garcia-Unzueta; A Berja; J A Miranda-Filloy; J M de Matias; C Gonzalez-Juanatey; J Llorca
Related Documents :
16204969 - Histamine h4 receptor expression in human synovial cells obtained from patients sufferi...
23612909 - Apolipoprotein e levels in the cerebrospinal fluid of north indian patients with alzhei...
19549229 - Comparison of the clinical features of recurrent aphthous stomatitis and beh??et's dise...
23287639 - Comparison of coronary plaque subtypes in male and female patients using 320-row mdcta.
1245949 - Renal arteriography in the evaluation of unexplained hypertension in children and adole...
19032819 - Listeria monocytogenes infection in patients with rheumatic diseases on tnf-alpha antag...
23258819 - Prevalence of unknown atrial fibrillation in patients with risk factors.
25340099 - Association between the proportion of globally sclerotic glomeruli and various morpholo...
24642479 - Potassium-binding resins: associations with serum chemistries and interdialytic weight ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  28     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-03-29     Completed Date:  2010-05-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  56-62     Citation Subset:  IM    
Division of Rheumatology, Hospital Xeral Calde, Lugo, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / blood*,  drug therapy*,  epidemiology
Cardiovascular Diseases / blood,  epidemiology
Chronic Disease
Cytokines / blood*,  immunology
Inflammation / blood*,  epidemiology
Metabolic Syndrome X / blood*,  epidemiology
Middle Aged
Nicotinamide Phosphoribosyltransferase / blood*,  immunology
Resistin / blood,  immunology
Risk Factors
Severity of Illness Index
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Cytokines; 0/RETN protein, human; 0/Resistin; 0/Tumor Necrosis Factor-alpha; 0/infliximab; EC Phosphoribosyltransferase; EC phosphoribosyltransferase, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased Risk of Adverse Pregnancy Outcomes for Women with Lupus Flares during Pregnancy: A Nationw...
Next Document:  Ulnar Neuropathy at the Elbow: how frequent is the idiopathic form?An ultrasonographic study in a co...